Publications by authors named "Norman Gitlin"

Claim this Profile
P
Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study.
A Sidney Barritt, Stephanie Watkins, Norman Gitlin, Samuel Klein, Anna S Lok

Hepatol Commun· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study.
A S Barritt, Norman Gitlin, Samuel Klein, Anna S Lok, Rohit Loomba

Contemp Clin Trials· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.
David Jones, Pol F Boudes, Mark G Swain, Christopher L Bowlus, Michael R Galambos, Norman Gitlin

Lancet Gastroenterol Hepatol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir.
Kris V Kowdley, David R Nelson, Jacob P Lalezari, Terry Box, Norman Gitlin

Liver Int· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study.
Paul Kwo, Norman Gitlin, Ronald Nahass, David Bernstein, Kyle Etzkorn

Hepatology· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients.
Gregory T Everson, Karen D Sims, Paul J Thuluvath, Eric Lawitz, Tarek Hassanein, Norman Gitlin

Liver Int· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data.
Julius M Wilder, Lennox J Jeffers, Natarajan Ravendhran, Mitchell L Shiffman, John Poulos, Norman Gitlin

Hepatology· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection.
Tarek Hassanein, Karen D Sims, Michael Bennett, Norman Gitlin, Eric Lawitz

J Hepatol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
David R Nelson, James N Cooper, Jacob P Lalezari, Eric Lawitz, Paul J Pockros, Norman Gitlin

Hepatology· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.
Eric Lawitz, Mark S Sulkowski, Reem Ghalib, Maribel Rodriguez-Torres, Zobair M Younossi, Norman Gitlin

Lancet· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
Nezam Afdhal, Stefan Zeuzem, Paul Kwo, Mario Chojkier, Norman Gitlin

N Engl J Med· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
Nezam Afdhal, K Rajender Reddy, David R Nelson, Eric Lawitz, Stuart C Gordon, Norman Gitlin

N Engl J Med· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of hepatic encephalopathy with rifaximin: more to think about.
Norman Gitlin

Hepatology· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population.
Peter M Wahl, Keith Rodgers, Sebastian Schneeweiss, Brian F Gage, Javed Butler, Norman Gitlin

Pharmacoepidemiol Drug Saf· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients.
Patrick Marcellin, Robert G Gish, Norman Gitlin, Jamie Heise, Deanine G Halliman

J Hepatol· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results.
Bruce R Bacon, Mitchell L Shiffman, Flavia Mendes, Reem Ghalib, Tarek Hassanein, Norman Gitlin

Hepatology· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels.
Stefan Zeuzem, Moisés Diago, Edward Gane, K Rajender Reddy, Paul Pockros, Norman Gitlin

Gastroenterology· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs.
Arthur L Weaver, Norman Gitlin

Arch Intern Med· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Manifestation of sarcoidosis during interferon and ribavirin therapy for chronic hepatitis C: a report of two cases.
Norman Gitlin

Eur J Gastroenterol Hepatol· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis